Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
Kodiak Sciences (Nasdaq: KOD) said senior management will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kodiak Sciences (Nasdaq: KOD) said senior management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026 at 1:30 p.m. PT.
A live webcast will be available on the company’s Events and Presentations page at http://ir.kodiak.com/ and will remain available for replay for a limited time after the event.
Details
News Market Reaction – KOD
On Jan 8, the first trading day after this news, KOD closed 1.66% below the previous close.
Data tracked by StockTitan Argus for the Jan 8 session.
Key Figures
- Conference edition
- 44th Annual
- J.P. Morgan Healthcare Conference appearance
- Presentation date
- January 12, 2026
- Scheduled J.P. Morgan Healthcare Conference presentation
- Presentation time
- 1:30 p.m. Pacific Time
- Timing of J.P. Morgan Healthcare Conference presentation
Historical Context
-
Closed $184M common stock offering at $23.00 per share.
-
Priced upsized common stock offering at $23.00 per share.
-
Announced proposed underwritten common stock offering under S-3.
-
Reported Q3 loss, low cash, and multiple Phase 3 timelines.
-
Announced CEO presentations at Jefferies and Evercore conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the presentation will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the event.
About Kodiak Sciences Inc.
Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. We are developing a portfolio of three late-stage clinical programs. Tarcocimab and KSI-501 are being explored in two BLA-facing Phase 3 studies in the retinal vascular diseases, targeting the
Kodiak®, Kodiak Sciences®, ABC®, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding Kodiak's plans, commitments, aspirations and goals related to Kodiak's drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled "Risk Factors" in Kodiak's most recent periodic report filed with the U.S. Securities and Exchange Commission ("SEC") as well as discussions of potential risks, uncertainties, and other important factors in Kodiak's subsequent filings with the SEC. All information in this press release is as of the date presented, and Kodiak undertakes no duty to update such information unless required by law.
View original content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-44th-annual-jp-morgan-healthcare-conference-302655850.html
SOURCE Kodiak Sciences Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.